RUBICON RESEARCH LIMITED
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant. The company was incorporated in 1999 and is based in Mumbai, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 19.1%
Concerns1
- Low return on equity of 5.0%
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 6 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.07 K Cr | β | βΉ168.00 Cr | β | β | 25.2% | 70.2% | 600.0% |
| Mar 2024 | βΉ631.00 Cr | β | βΉ24.00 Cr | β | β | 5.0% | 60.2% | -241.2% |
| Mar 2023 | βΉ394.00 Cr | β | βΉ-17.00 | β | β | -5.9% | -1.5% | -200.0% |
| Mar 2022 | βΉ400.00 Cr | β | βΉ17.00 Cr | β | β | 4.0% | 20.8% | -67.9% |
| Mar 2021 | βΉ331.00 Cr | β | βΉ53.00 Cr | β | β | 12.9% | 25.9% | -10.2% |
| Mar 2020 | βΉ263.00 Cr | β | βΉ59.00 Cr | β | β | 16.6% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | Mar 2025 |
|---|---|
| Revenue / Net Sales | 1,074 |
| Total Expenses | 803 |
| EBIT / Operating Profit | 271 |
| OPM % | 25% |
| Other Income | 19 |
| Finance Costs | 34 |
| Depreciation & Amortisation | 32 |
| Profit Before Tax | 223 |
| Tax % | 25% |
| Net Profit / PAT | 168 |
| EPS (βΉ) | 10.87 |
| Dividend Payout % | 0% |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| RUBICON RESEARCH LIMITEDthis co. | βΉ11.14 K Cr | βΉ1.07 K Cr | 65.00 | 0.00 | 115.20 | 70.2% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |